The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 3, 2006, Pages 310-320

  Marier, Jean Francois ^a   Guilbaud, Rudolf ^a   Kambhampati, Siva Rama Prasad ^a   Mathew, Philip ^a   Moberly, James ^b   Lee, James ^b   Salazar, Daniel E ^b  

^a MDS Inc   (Canada)

^b DAIICHI SANKYO INC   (United States)

Author keywords

AST 120; Losartan, drug interaction; Oral adsorbent; Pharmacokinetics

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; AST 120; LOSARTAN POTASSIUM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG EFFECT; FEEDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADSORPTION; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARBON; CROSS-OVER STUDIES; DIETARY FATS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL AGENTS; HUMANS; IMIDAZOLES; LOSARTAN; MALE; OXIDES; TETRAZOLES; TIME FACTORS;

EID: 32944455285     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005284388     Document Type: Article

References (16)

1. Koide K, Sano M, Takeda F, Momose T, Koshikawa S, Akizawa T. A study of oral adsorbent in chronic renal failure. Biomater Artif Cells Immobilization Biotechnol. 1991 ; 19: 147-166.
2. Niwa T, Yazawa T, Ise M, et al. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats. Nephron. 1991 ; 57: 84-88.
3. Yoshida Y, Sakai T, Ise M. Effects of oral adsorbent in the rat model of chronic renal failure. Nephron. 1992 ; 62: 305-314.
4. Aoyama I, Niwa T. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats. Am J Kidney Dis. 2001 ; 37 (1 suppl 2). S7 - S12.
5. Ishikawa I, Araya M, Hayama T, Sugano M, Yamato H, Ise M. Effect of oral adsorbent (AST-120) on renal function, acquired renal cysts and aortic calcification in rats with adriamycin nephropathy. Nephron. 2002 ; 92: 399-406.
6. Investigator's brochure for AST-120 (AST-120). Tokyo, Japan: Kureha Chemical Industry Co, Ltd ; July 2002.
7. Honda Y, Nakano M. Studies of pharmacological interactions of AST-120 capsule 200 with drugs. Clin Rep. 1994 ; 28: 2873-2881.
8. Losartan. In: Martindale: The Complete Drug Reference[monograph]. London, UK: Pharmaceutical Press. Available at: http://www.csi.micromedex.com.
9. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993 ; 21: 704-713.
10. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993 ; 35: 290-297.
11. Sasaki M, Fujimura A, Harada K, Sunaga K, Ebihara A. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Pharmacol. 1996 ; 36: 403-408.
12. Ohrvik J. Nonparametric methods in crossover trials. Biom J. 1998 ; 40: 771-789.
13. Rowland M, Towzer TN. Clinical Pharmacokinetics: Concepts and Applications. Philadelphia, Pa: Lippincott Williams & Wilkins ; 1995.
14. Hauschke D, Steinijans VW, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990 ; 28: 72-78.
15. Senn S. Cross-over Trials in Clinical Research. 2nd ed. West Sussex, UK: John Wiley & Sons ; 2002.
16. US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research. Guidance for industry, food-effect bioavailability and fed bioequivalence studies. December 2002. Available at: http://www.fda.gov/cder/guidance/5194fnl.pdf.